查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1466634

注射市場：按分子類型、藥物類別、注射途徑和應用分類 - 2024-2030 年全球預測

Injectable Drugs Market by Molecule Type (Large Molecule, Small Molecule), Drug Class (Blood Factors, Cytokines, Immunoglobulin), Injection Routes, Application - Global Forecast 2024-2030
出版日期: | 出版商: 360iResearch | 英文 199 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計2023年注射劑市場規模為5,633億美元，預計2024年將達6,170.4億美元，2030年將達1,0885.5億美元，複合年成長率為9.86%。

注射劑市場包括透過靜脈（IV）、肌肉內（IM）和皮下（SC）注射途徑進行的藥物和治療方法的銷售和分銷。經營抗生素、胰島素、疫苗、腫瘤治療藥等治療各種疾病所必需的藥品。注射劑有多種用途，從緊急醫療護理到治療慢性疾病的日常用藥。除了在醫院和診所使用之外，自動注射器的進步也導致其在自我護理環境中使用。有幾個因素正在推動注射藥物市場的開拓，包括慢性疾病負擔的增加、預填充藥物和自注射藥物的使用增加以及穩定的藥物輸送載體用於癌症治療的持續實踐。然而，該市場面臨研發成本高、監管合規成本以及惡劣條件下複雜的製造流程等限制和挑戰。同時，由於注射劑的快速開發和核准以及注射劑製造商之間的策略聯盟，新的機會正在出現。此外，提高藥物傳遞的安全性、便利性和有效性可以提高患者的依從性並改善結果。

主要市場統計
基準年[2023] 5633億美元
預測年份 [2024] 6170.4億美元
預測年份 [2030] 1,088,550 百萬美元
複合年成長率（%） 9.86%

藥物類別：用於細胞訊號傳導的細胞激素注射越來越受歡迎

凝血必需的血液因子是用於治療血友病和其他凝血障礙以及預防出血的注射。血液因子可以從人類血漿中或透過重組基因技術獲得。 A型血友病是需要這些治療的最常見疾病。細胞激素是一類廣泛的可注射蛋白質，對於免疫系統中的細胞訊號傳導非常重要。它們包括干擾素、白細胞介素和集落刺激因子，用於治療癌症和自體免疫疾病。免疫球蛋白是免疫系統的重要組成部分，常用於各種免疫力缺乏症候群和自體免疫疾病。這些藥物提供免疫系統對抗病原體所需的抗體。胰島素是肽激素，對於調節血糖值至關重要。胰島素主要用於糖尿病患者，當身體無法自然產生足夠的胰島素時使用。單株抗體 (mAb) 是模仿免疫系統抵抗有害病原體能力的工程分子。這些藥物正在改變多種疾病的治療方法，包括癌症、自體免疫疾病和感染疾病。肽激素包括胰島素以外的多種注射激素，例如生長激素、抗糖尿病Glucagon-Like Peptide-1(GLP-1)促效劑和抑鈣素。這些激素發揮多種作用，包括調節生長、葡萄糖代謝和骨穩態。

應用：擴大注射劑在自體免疫疾病治療的應用

自體免疫疾病注射可治療多種疾病，包括類風濕性關節炎、多發性硬化症和克隆氏症。生物製藥是注射藥物的子類，通常採用有針對性的方法來調節免疫系統。注射劑是首選，因為它們起效快且比口服藥物療效更高。心血管疾病注射劑旨在治療心臟衰竭、心律不整和高血壓等疾病。這些注射通常在緊急情況下發揮關鍵作用，在抗凝血劑和凝血因子等治療延遲可能致命時提供快速治療。在感染疾病中，注射藥物對於抗病毒、抗生素和抗真菌藥物至關重要，特別是當需要快速達到高血中濃度或無法口服給藥時。它們對於抗病毒藥物、抗生素和抗真菌藥物至關重要，特別是當需要快速達到高血中濃度或無法口服給藥時。神經注射劑可治療阿茲海默症、多發性硬化症和偏頭痛等疾病。單株抗體在這一領域很重要，因為它們能夠穿過血腦障壁。癌症領域的注射藥物包括化療藥物、荷爾蒙療法藥物、免疫治療藥物等，對於各種癌症的治療至關重要。注射劑是優選的，因為需要達到高局部濃度並避免胃腸道吸收問題。注射性疼痛管理藥物，如鴉片類藥物和非類固醇消炎劑(NSAID)，因其在急性、慢性和術後疼痛管理中的速度和有效性而受到青睞。注射應用領域的比較表明，每個領域都滿足醫療保健領域的獨特需求。自體免疫疾病需要長期治療方法，注射劑可以提供持久的緩解。相較之下，注射心血管藥物往往較為緊急，需要快速的生理反應。用於感染疾病的注射藥物必須具有廣泛且快速的作用，以有效控制感染疾病。在神經病學領域，考慮到血腦障壁的問題，注射劑具有能夠標靶給藥的優點。注射型癌症藥物透過在腫瘤部位高濃度輸送來提供標靶治療的好處。最後，注射疼痛管理可以立即緩解口服藥物通常無法達到的急性、嚴重疼痛。

區域洞察

在美洲，特別是在美國和加拿大，由於糖尿病和癌症等疾病的流行，注射藥物的需求量很大。先進的醫療基礎設施和高昂的人均醫療成本正在推動新注射技術的創新和採用。在這些市場中，藥物功效、安全性和易用性影響顧客的購買行為。由於巴西、阿根廷和智利等國醫療保健設施的改善、經濟穩定性的增強以及政府對醫療改革的支持，南美注射市場正在穩步成長。歐洲擁有發達的醫療體系和優惠的報銷政策，注射劑市場正作為新興市場發展。由於先進治療方法的普及，東歐國家的成長率正在加速。包括沙烏地阿拉伯和阿拉伯聯合大公國在內的中東地區因其發達的醫療基礎設施和不斷增加的私營部門投資而成為一個充滿前景的市場。與此同時，非洲在引入注射療法方面正在取得進展，但面臨著負擔能力和藥物取得的挑戰。由於經濟成長、醫療保健行業的擴張以及生物製藥研究投資的增加，亞太地區已成為成長最快的注射劑市場。中國、印度和日本等國家處於領先地位，對學名藥和創新注射劑的需求都很高。在中國，國內製造和引進外資活躍，服務廣大的國內市場。日本以其技術進步而聞名，並大力投資藥物研發，包括下一代注射劑。印度的製藥業發展迅速，是一個龐大的注射劑市場。低成本製造和不斷壯大的中階有利於影響更實惠的注射藥物選擇的購買行為。

FPNV定位矩陣

FPNV 定位矩陣對於評估注射劑市場至關重要。我們檢視與業務策略和產品滿意度相關的關鍵指標，以對供應商進行全面評估。這種深入的分析使用戶能夠根據自己的要求做出明智的決策。根據評估，供應商被分為四個成功程度不同的像限：前沿（F）、探路者（P）、利基（N）和重要（V）。

市場佔有率分析

市場佔有率分析是一種綜合工具，可以對注射劑市場供應商的現狀進行深入而深入的研究。全面比較和分析供應商在整體收益、基本客群和其他關鍵指標方面的貢獻，以便更好地了解公司的績效及其在爭奪市場佔有率時面臨的挑戰。此外，該分析還提供了對該行業競爭特徵的寶貴見解，包括在研究基準年觀察到的累積、分散主導地位和合併特徵等因素。這種詳細程度的提高使供應商能夠做出更明智的決策並制定有效的策略，從而在市場上獲得競爭優勢。

本報告在以下方面提供了寶貴的見解：

1. 市場滲透率：提供有關主要企業所服務的市場的全面資訊。

2. 市場開拓：我們深入研究利潤豐厚的新興市場，並分析其在成熟細分市場的滲透率。

3. 市場多元化：提供有關新產品發布、開拓地區、最新發展和投資的詳細資訊。

4.競爭力評估及資訊：對主要企業的市場佔有率、策略、產品、認證、監管狀況、專利狀況、製造能力等進行全面評估。

5. 產品開發與創新：提供對未來技術、研發活動和突破性產品開發的見解。

本報告解決了以下關鍵問題：

1.注射劑市場規模及預測如何？

2.注射劑市場預測期內需要考慮投資的產品、細分市場、應用和領域有哪些？

3.注射劑市場的技術趨勢和法規結構是什麼？

4.注射劑市場主要供應商的市場佔有率是多少？

5.進入注射劑市場的合適模式和策略手段是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 慢性病負擔增加
      • 預填充和自行注射藥物的使用增加
      • 受控藥物傳輸載體在癌症治療中的持續實踐
    • 抑制因素
      • 產品回收數量增加
    • 機會
      • 注射劑的快速開發和核准
      • 注射劑製造商之間的策略聯盟
    • 任務
      • 製造流程複雜，注射劑短缺
  • 市場區隔分析
    • 藥物類別：用於細胞訊號傳導的細胞細胞激素注射蛋白越來越受歡迎
    • 應用：擴大注射劑在自體免疫疾病治療的應用
  • 市場趨勢分析
  • 俄羅斯-烏克蘭衝突的累積影響
  • 高通膨的累積效應
  • 波特五力分析
  • 價值鍊和關鍵路徑分析
  • 法規結構分析
  • 客戶客製化

第6章注射劑市場：依分子類型

  • 高分子
  • 小分子

第7章注射劑市場：依藥物類別

  • 血液因素
  • 細胞激素
  • 免疫球蛋白
  • 胰島素
  • 單株抗體
  • 肽激素

第8章注射劑市場：依注射途徑

  • 肌肉注射
  • 眼
  • 椎管內的
  • 靜脈
  • 皮下的

第9章注射劑市場：依應用分類

  • 自體免疫疾病
  • 心血管疾病
  • 感染疾病
  • 神經病學
  • 腫瘤學
  • 疼痛

第10章美洲注射劑市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第11章亞太注射劑市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第12章 歐洲、中東和非洲注射市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第13章競爭格局

  • 市場佔有率分析（2023）
  • FPNV定位矩陣（2023）
  • 競爭情境分析
    • Sun Pharma 與 Taro 宣布合併協議
    • Glenmark 在印度推出流行抗糖尿病藥物Liraglutide的生物相似藥
    • 百時美施貴寶的Opdivo注射液達到腎癌臨床試驗的關鍵目標

第14章競爭組合

  • 主要企業簡介
  • 主要產品系列
Product Code: MRR-742BD517FCA4

[199 Pages Report] The Injectable Drugs Market size was estimated at USD 563.30 billion in 2023 and expected to reach USD 617.04 billion in 2024, at a CAGR 9.86% to reach USD 1,088.55 billion by 2030.

The injectable drugs market comprises sales and distribution of medications and therapies that are administered through intravenous (IV), intramuscular (IM), or subcutaneous (SC) injection routes. The market caters to various drugs, including antibiotics, insulin, vaccines, and oncology treatments, that are integral in treating multiple diseases and medical conditions. Injectable drugs have diverse applications ranging from emergency care to routine administration of chronic disease medications. They are used in hospitals, clinics, and, increasingly, self-care settings due to advancements in auto-injection devices. Several factors, such as the rising burden of chronic diseases, the growing use of prefilled and self-injectable drugs, and the ongoing practice of steady drug delivery vehicles for cancer treatment, drive the development of the injectable drugs market. However, the market faces limitations and challenges, including high research and development costs, regulatory compliance costs, and complex manufacturing processes under stringent conditions. On the other hand, new opportunities are emerging due to rapid developments and approvals in injectable drugs and strategic alliances among manufacturers for injectable drugs. Moreover, improving drug delivery methods' safety, convenience, and efficacy can lead to increased patient compliance and better outcomes.

KEY MARKET STATISTICS
Base Year [2023] USD 563.30 billion
Estimated Year [2024] USD 617.04 billion
Forecast Year [2030] USD 1,088.55 billion
CAGR (%) 9.86%

Drug Class: Increasing preference for cytokines injectable protein for cell signaling

Blood factors, essential for blood clotting, are injectable agents used to treat and prevent bleeding in individuals with hemophilia and other clotting disorders. They are derived either from human plasma or through recombinant technology. Hemophilia A and B are the most common disorders requiring these treatments. Cytokines are a broad category of injectable proteins critical in cell signaling within the immune system. They include interferons, interleukins, and colony-stimulating factors and are used in treating cancers and autoimmune conditions. Immunoglobulins are essential immune system components commonly used for various immunodeficiency syndromes and autoimmune diseases. These drugs provide necessary antibodies for the immune system to combat pathogens. Insulin is a peptide hormone vital for the regulation of blood glucose levels. It is primarily administered to individuals with diabetes when their body cannot produce sufficient insulin naturally. Monoclonal Antibodies (mAbs) are engineered molecules that imitate the immune system's capacity to fight off harmful pathogens. These drugs have transformed treatment across a spectrum of conditions, including cancer, autoimmune diseases, and infectious diseases. Peptide hormones encompass a variety of injectable hormones other than insulin, such as growth hormone, glucagon-like peptide-1 (GLP-1) agonists for diabetes, and calcitonin. They play various roles, including regulating growth, glucose metabolism, and bone homeostasis.

Application: Growing application of injectable drugs for treating autoimmune diseases

Injectable drugs for autoimmune diseases treat various conditions, including rheumatoid arthritis, multiple sclerosis, and Crohn's disease. Biologics, a subclass of injectable drugs, are often prescribed due to their targeted approach to modulating the immune system. The need-based preference for injectables stems from their quick onset of action and higher efficacy than oral medications. Injectable drugs for cardiovascular diseases aim to manage conditions such as heart failure, arrhythmia, and hypertension. These injections are often critical in emergency settings, providing rapid action where delayed treatment, such as anticoagulants or clotting factors, can be fatal. For infectious diseases, injectable drugs are crucial for antivirals, antibiotics, and antifungals, especially when high blood concentrations are required quickly, or oral administration is not feasible. They are critical in hospital settings for severe or resistant infections. Neurology injectables treat disorders, including Alzheimer's, multiple sclerosis, and migraines. Monoclonal antibodies are significant in this segment for their ability to cross the blood-brain barrier. Oncology injectables include chemotherapy agents, hormonal therapies, and immunotherapies, essential for treating various cancers. The preference for injections comes from the need to achieve high local concentration and to bypass gastrointestinal absorption issues. Injectable drugs for pain management, such as opioids and nonsteroidal anti-inflammatory drugs (NSAIDs), are preferred in acute, chronic, and post-operative pain management for their speed and efficacy. In comparing the application segments for injectable drugs, it is apparent that each serves a distinct need in the healthcare sphere. Autoimmune diseases require long-term treatment regimens where injectables offer sustained relief. In contrast, cardiovascular injectable drugs are often emergency-related and demand rapid physiological responses. Infectious disease injectables must be broad-spectrum and rapidly acting to curb infections effectively. Neurology benefits from the targeted delivery achieved by injectables, a distinct advantage given the blood-brain barrier challenge. Injectable oncology drugs offer the benefit of targeted therapy with higher concentrations at the tumor site. Lastly, pain management with injectables provides immediate relief from acute and severe pain, which is often unattainable with oral medications.

Regional Insights

In the Americas, particularly in the United States and Canada, there is a high demand for injectable drugs due to the prevalence of diseases such as diabetes and cancer. Advanced healthcare infrastructure and high per capita healthcare expenditure drive the innovation and adoption of new injection technologies. Drug efficacy, safety profiles, and ease of use influence customer purchasing behavior in these markets. South America's market for injectable drugs is growing steadily due to improving healthcare facilities, increasing economic stability, and governmental support for healthcare reforms in countries such as Brazil, Argentina, and Chile. Europe represents a developing injectable drug market with well-established healthcare systems and favorable reimbursement policies. Eastern European countries are experiencing faster growth rates due to increased accessibility to advanced therapeutics. The Middle East, with countries such as Saudi Arabia and the UAE, shows a promising injectable drugs market due to rising healthcare infrastructure and increasing private sector investments. Africa, on the other hand, is progressively adopting injectable drug therapies but faces challenges related to affordability and access to medicine. The APAC region is emerging as the fastest-growing market for injectable drugs, driven by economic growth, expanding healthcare sectors, and increasing investments in biopharmaceutical research. Countries such as China, India, and Japan are at the forefront, with a high demand for both generic and innovative injectable drugs. In China, local manufacturing and foreign investment are extensive, catering to a vast domestic market. Japan is known for its technological advancements and invests heavily in pharmaceutical R&D, including next-generation injectable treatments. With a burgeoning pharmaceutical industry, India offers a large market for injectable drugs. Low-cost manufacturing and a growing middle class impact purchasing behaviors favorably toward more affordable injectable options.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Injectable Drugs Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Injectable Drugs Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Injectable Drugs Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, AbbVie Inc., Amgen Inc., AstraZeneca PLC, Baxter International Inc., Biogen Inc., Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company, Chiesi Farmaceutici S.p.A., Cipla Limited, Daiichi Sankyo Co., Ltd., Dr. Reddy's Laboratories Ltd., Eagle Pharmaceuticals, Inc., Eli Lilly and Company, EVER Neuro Pharma GmbH, F. Hoffmann-La Roche Ltd., Ferring B.V., Fresenius Kabi AG, Gilead Sciences, Inc., GlaxoSmithKline PLC, Johnson & Johnson Services, Inc., Merck & Co., Inc., Novartis AG, Novo Nordisk A/S, Pfizer Inc., Sanofi S.A., SCHOTT PHARMA AG & CO. KGAA, Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., and Viatris Inc..

Market Segmentation & Coverage

This research report categorizes the Injectable Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Molecule Type
    • Large Molecule
    • Small Molecule
  • Drug Class
    • Blood Factors
    • Cytokines
    • Immunoglobulin
    • Insulin
    • Monoclonal Antibodies
    • Peptide Hormone
  • Injection Routes
    • Intramuscular
    • Intraocular
    • Intrathecal
    • Intravenous
    • Subcutaneous
  • Application
    • Autoimmune Diseases
    • Cardiovascular Diseases
    • Infectious Diseases
    • Neurology
    • Oncology
    • Pain
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Injectable Drugs Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Injectable Drugs Market?

3. What are the technology trends and regulatory frameworks in the Injectable Drugs Market?

4. What is the market share of the leading vendors in the Injectable Drugs Market?

5. Which modes and strategic moves are suitable for entering the Injectable Drugs Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising Burden of Chronic Diseases
      • 5.1.1.2. Growing Use of Prefilled and Self-Injectable Drugs
      • 5.1.1.3. Ongoing Practice of Controlled Drug Delivery Vehicles for Cancer Treatment
    • 5.1.2. Restraints
      • 5.1.2.1. Rise in Incidences of Product Recall
    • 5.1.3. Opportunities
      • 5.1.3.1. Rapid Developments and Approvals in Injectable Drugs
      • 5.1.3.2. Strategic Alliances Among Manufacturers for Injectable Drugs
    • 5.1.4. Challenges
      • 5.1.4.1. Complex Manufacturing Process and Shortages of Injectable Drugs
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Drug Class: Increasing preference for cytokines injectable protein for cell signaling
    • 5.2.2. Application: Growing application of injectable drugs for treating autoimmune diseases
  • 5.3. Market Trend Analysis
  • 5.4. Cumulative Impact of Russia-Ukraine Conflict
  • 5.5. Cumulative Impact of High Inflation
  • 5.6. Porter's Five Forces Analysis
    • 5.6.1. Threat of New Entrants
    • 5.6.2. Threat of Substitutes
    • 5.6.3. Bargaining Power of Customers
    • 5.6.4. Bargaining Power of Suppliers
    • 5.6.5. Industry Rivalry
  • 5.7. Value Chain & Critical Path Analysis
  • 5.8. Regulatory Framework Analysis
  • 5.9. Client Customization

6. Injectable Drugs Market, by Molecule Type

  • 6.1. Introduction
  • 6.2. Large Molecule
  • 6.3. Small Molecule

7. Injectable Drugs Market, by Drug Class

  • 7.1. Introduction
  • 7.2. Blood Factors
  • 7.3. Cytokines
  • 7.4. Immunoglobulin
  • 7.5. Insulin
  • 7.6. Monoclonal Antibodies
  • 7.7. Peptide Hormone

8. Injectable Drugs Market, by Injection Routes

  • 8.1. Introduction
  • 8.2. Intramuscular
  • 8.3. Intraocular
  • 8.4. Intrathecal
  • 8.5. Intravenous
  • 8.6. Subcutaneous

9. Injectable Drugs Market, by Application

  • 9.1. Introduction
  • 9.2. Autoimmune Diseases
  • 9.3. Cardiovascular Diseases
  • 9.4. Infectious Diseases
  • 9.5. Neurology
  • 9.6. Oncology
  • 9.7. Pain

10. Americas Injectable Drugs Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Injectable Drugs Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Injectable Drugs Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
    • 13.3.1. Sun Pharma and Taro announce merger agreement
    • 13.3.2. Glenmark launched Biosimilar of Popular Anti-Diabetic Drug, Liraglutide, in India
    • 13.3.3. Bristol Myers' injectable form of Opdivo meets main goal in kidney cancer trial

14. Competitive Portfolio

  • 14.1. Key Company Profiles
  • 14.2. Key Product Portfolio

LIST OF FIGURES

  • FIGURE 1. INJECTABLE DRUGS MARKET RESEARCH PROCESS
  • FIGURE 2. INJECTABLE DRUGS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL INJECTABLE DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL INJECTABLE DRUGS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. GLOBAL INJECTABLE DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. INJECTABLE DRUGS MARKET DYNAMICS
  • FIGURE 7. GLOBAL INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2023 VS 2030 (%)
  • FIGURE 8. GLOBAL INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. GLOBAL INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2023 VS 2030 (%)
  • FIGURE 10. GLOBAL INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. GLOBAL INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2023 VS 2030 (%)
  • FIGURE 12. GLOBAL INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. GLOBAL INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 14. GLOBAL INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. AMERICAS INJECTABLE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 16. AMERICAS INJECTABLE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. UNITED STATES INJECTABLE DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 18. UNITED STATES INJECTABLE DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. ASIA-PACIFIC INJECTABLE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 20. ASIA-PACIFIC INJECTABLE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA INJECTABLE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA INJECTABLE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 23. INJECTABLE DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 24. INJECTABLE DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. INJECTABLE DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL INJECTABLE DRUGS MARKET SIZE, 2018-2023 (USD MILLION)
  • TABLE 4. GLOBAL INJECTABLE DRUGS MARKET SIZE, 2024-2030 (USD MILLION)
  • TABLE 5. GLOBAL INJECTABLE DRUGS MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 6. GLOBAL INJECTABLE DRUGS MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 7. GLOBAL INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2023 (USD MILLION)
  • TABLE 8. GLOBAL INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2024-2030 (USD MILLION)
  • TABLE 9. GLOBAL INJECTABLE DRUGS MARKET SIZE, BY LARGE MOLECULE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 10. GLOBAL INJECTABLE DRUGS MARKET SIZE, BY LARGE MOLECULE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 11. GLOBAL INJECTABLE DRUGS MARKET SIZE, BY SMALL MOLECULE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 12. GLOBAL INJECTABLE DRUGS MARKET SIZE, BY SMALL MOLECULE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 13. GLOBAL INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 14. GLOBAL INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 15. GLOBAL INJECTABLE DRUGS MARKET SIZE, BY BLOOD FACTORS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 16. GLOBAL INJECTABLE DRUGS MARKET SIZE, BY BLOOD FACTORS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 17. GLOBAL INJECTABLE DRUGS MARKET SIZE, BY CYTOKINES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 18. GLOBAL INJECTABLE DRUGS MARKET SIZE, BY CYTOKINES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 19. GLOBAL INJECTABLE DRUGS MARKET SIZE, BY IMMUNOGLOBULIN, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 20. GLOBAL INJECTABLE DRUGS MARKET SIZE, BY IMMUNOGLOBULIN, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 21. GLOBAL INJECTABLE DRUGS MARKET SIZE, BY INSULIN, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 22. GLOBAL INJECTABLE DRUGS MARKET SIZE, BY INSULIN, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 23. GLOBAL INJECTABLE DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 24. GLOBAL INJECTABLE DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 25. GLOBAL INJECTABLE DRUGS MARKET SIZE, BY PEPTIDE HORMONE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 26. GLOBAL INJECTABLE DRUGS MARKET SIZE, BY PEPTIDE HORMONE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 27. GLOBAL INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2018-2023 (USD MILLION)
  • TABLE 28. GLOBAL INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2024-2030 (USD MILLION)
  • TABLE 29. GLOBAL INJECTABLE DRUGS MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 30. GLOBAL INJECTABLE DRUGS MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 31. GLOBAL INJECTABLE DRUGS MARKET SIZE, BY INTRAOCULAR, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 32. GLOBAL INJECTABLE DRUGS MARKET SIZE, BY INTRAOCULAR, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 33. GLOBAL INJECTABLE DRUGS MARKET SIZE, BY INTRATHECAL, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 34. GLOBAL INJECTABLE DRUGS MARKET SIZE, BY INTRATHECAL, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 35. GLOBAL INJECTABLE DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 36. GLOBAL INJECTABLE DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 37. GLOBAL INJECTABLE DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 38. GLOBAL INJECTABLE DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 39. GLOBAL INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 40. GLOBAL INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 41. GLOBAL INJECTABLE DRUGS MARKET SIZE, BY AUTOIMMUNE DISEASES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 42. GLOBAL INJECTABLE DRUGS MARKET SIZE, BY AUTOIMMUNE DISEASES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 43. GLOBAL INJECTABLE DRUGS MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 44. GLOBAL INJECTABLE DRUGS MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 45. GLOBAL INJECTABLE DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 46. GLOBAL INJECTABLE DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 47. GLOBAL INJECTABLE DRUGS MARKET SIZE, BY NEUROLOGY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 48. GLOBAL INJECTABLE DRUGS MARKET SIZE, BY NEUROLOGY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 49. GLOBAL INJECTABLE DRUGS MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 50. GLOBAL INJECTABLE DRUGS MARKET SIZE, BY ONCOLOGY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 51. GLOBAL INJECTABLE DRUGS MARKET SIZE, BY PAIN, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 52. GLOBAL INJECTABLE DRUGS MARKET SIZE, BY PAIN, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 53. AMERICAS INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2023 (USD MILLION)
  • TABLE 54. AMERICAS INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2024-2030 (USD MILLION)
  • TABLE 55. AMERICAS INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 56. AMERICAS INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 57. AMERICAS INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2018-2023 (USD MILLION)
  • TABLE 58. AMERICAS INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2024-2030 (USD MILLION)
  • TABLE 59. AMERICAS INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 60. AMERICAS INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 61. AMERICAS INJECTABLE DRUGS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 62. AMERICAS INJECTABLE DRUGS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 63. ARGENTINA INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2023 (USD MILLION)
  • TABLE 64. ARGENTINA INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2024-2030 (USD MILLION)
  • TABLE 65. ARGENTINA INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 66. ARGENTINA INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 67. ARGENTINA INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2018-2023 (USD MILLION)
  • TABLE 68. ARGENTINA INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2024-2030 (USD MILLION)
  • TABLE 69. ARGENTINA INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 70. ARGENTINA INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 71. BRAZIL INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2023 (USD MILLION)
  • TABLE 72. BRAZIL INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2024-2030 (USD MILLION)
  • TABLE 73. BRAZIL INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 74. BRAZIL INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 75. BRAZIL INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2018-2023 (USD MILLION)
  • TABLE 76. BRAZIL INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2024-2030 (USD MILLION)
  • TABLE 77. BRAZIL INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 78. BRAZIL INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 79. CANADA INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2023 (USD MILLION)
  • TABLE 80. CANADA INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2024-2030 (USD MILLION)
  • TABLE 81. CANADA INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 82. CANADA INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 83. CANADA INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2018-2023 (USD MILLION)
  • TABLE 84. CANADA INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2024-2030 (USD MILLION)
  • TABLE 85. CANADA INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 86. CANADA INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 87. MEXICO INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2023 (USD MILLION)
  • TABLE 88. MEXICO INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2024-2030 (USD MILLION)
  • TABLE 89. MEXICO INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 90. MEXICO INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 91. MEXICO INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2018-2023 (USD MILLION)
  • TABLE 92. MEXICO INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2024-2030 (USD MILLION)
  • TABLE 93. MEXICO INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 94. MEXICO INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 95. UNITED STATES INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2023 (USD MILLION)
  • TABLE 96. UNITED STATES INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2024-2030 (USD MILLION)
  • TABLE 97. UNITED STATES INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 98. UNITED STATES INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 99. UNITED STATES INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2018-2023 (USD MILLION)
  • TABLE 100. UNITED STATES INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2024-2030 (USD MILLION)
  • TABLE 101. UNITED STATES INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 102. UNITED STATES INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 103. UNITED STATES INJECTABLE DRUGS MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
  • TABLE 104. UNITED STATES INJECTABLE DRUGS MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
  • TABLE 105. ASIA-PACIFIC INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2023 (USD MILLION)
  • TABLE 106. ASIA-PACIFIC INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2024-2030 (USD MILLION)
  • TABLE 107. ASIA-PACIFIC INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 108. ASIA-PACIFIC INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 109. ASIA-PACIFIC INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2018-2023 (USD MILLION)
  • TABLE 110. ASIA-PACIFIC INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2024-2030 (USD MILLION)
  • TABLE 111. ASIA-PACIFIC INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 112. ASIA-PACIFIC INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 113. ASIA-PACIFIC INJECTABLE DRUGS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 114. ASIA-PACIFIC INJECTABLE DRUGS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 115. AUSTRALIA INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2023 (USD MILLION)
  • TABLE 116. AUSTRALIA INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2024-2030 (USD MILLION)
  • TABLE 117. AUSTRALIA INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 118. AUSTRALIA INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 119. AUSTRALIA INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2018-2023 (USD MILLION)
  • TABLE 120. AUSTRALIA INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2024-2030 (USD MILLION)
  • TABLE 121. AUSTRALIA INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 122. AUSTRALIA INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 123. CHINA INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2023 (USD MILLION)
  • TABLE 124. CHINA INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2024-2030 (USD MILLION)
  • TABLE 125. CHINA INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 126. CHINA INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 127. CHINA INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2018-2023 (USD MILLION)
  • TABLE 128. CHINA INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2024-2030 (USD MILLION)
  • TABLE 129. CHINA INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 130. CHINA INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 131. INDIA INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2023 (USD MILLION)
  • TABLE 132. INDIA INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2024-2030 (USD MILLION)
  • TABLE 133. INDIA INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 134. INDIA INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 135. INDIA INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2018-2023 (USD MILLION)
  • TABLE 136. INDIA INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2024-2030 (USD MILLION)
  • TABLE 137. INDIA INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 138. INDIA INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 139. INDONESIA INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2023 (USD MILLION)
  • TABLE 140. INDONESIA INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2024-2030 (USD MILLION)
  • TABLE 141. INDONESIA INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 142. INDONESIA INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 143. INDONESIA INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2018-2023 (USD MILLION)
  • TABLE 144. INDONESIA INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2024-2030 (USD MILLION)
  • TABLE 145. INDONESIA INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 146. INDONESIA INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 147. JAPAN INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2023 (USD MILLION)
  • TABLE 148. JAPAN INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2024-2030 (USD MILLION)
  • TABLE 149. JAPAN INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 150. JAPAN INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 151. JAPAN INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2018-2023 (USD MILLION)
  • TABLE 152. JAPAN INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2024-2030 (USD MILLION)
  • TABLE 153. JAPAN INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 154. JAPAN INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 155. MALAYSIA INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2023 (USD MILLION)
  • TABLE 156. MALAYSIA INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2024-2030 (USD MILLION)
  • TABLE 157. MALAYSIA INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 158. MALAYSIA INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 159. MALAYSIA INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2018-2023 (USD MILLION)
  • TABLE 160. MALAYSIA INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2024-2030 (USD MILLION)
  • TABLE 161. MALAYSIA INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 162. MALAYSIA INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 163. PHILIPPINES INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2023 (USD MILLION)
  • TABLE 164. PHILIPPINES INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2024-2030 (USD MILLION)
  • TABLE 165. PHILIPPINES INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 166. PHILIPPINES INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 167. PHILIPPINES INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2018-2023 (USD MILLION)
  • TABLE 168. PHILIPPINES INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2024-2030 (USD MILLION)
  • TABLE 169. PHILIPPINES INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 170. PHILIPPINES INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 171. SINGAPORE INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2023 (USD MILLION)
  • TABLE 172. SINGAPORE INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2024-2030 (USD MILLION)
  • TABLE 173. SINGAPORE INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 174. SINGAPORE INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 175. SINGAPORE INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2018-2023 (USD MILLION)
  • TABLE 176. SINGAPORE INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2024-2030 (USD MILLION)
  • TABLE 177. SINGAPORE INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 178. SINGAPORE INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 179. SOUTH KOREA INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2023 (USD MILLION)
  • TABLE 180. SOUTH KOREA INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2024-2030 (USD MILLION)
  • TABLE 181. SOUTH KOREA INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 182. SOUTH KOREA INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 183. SOUTH KOREA INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2018-2023 (USD MILLION)
  • TABLE 184. SOUTH KOREA INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2024-2030 (USD MILLION)
  • TABLE 185. SOUTH KOREA INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 186. SOUTH KOREA INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 187. TAIWAN INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2023 (USD MILLION)
  • TABLE 188. TAIWAN INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2024-2030 (USD MILLION)
  • TABLE 189. TAIWAN INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 190. TAIWAN INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 191. TAIWAN INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2018-2023 (USD MILLION)
  • TABLE 192. TAIWAN INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2024-2030 (USD MILLION)
  • TABLE 193. TAIWAN INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 194. TAIWAN INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 195. THAILAND INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2023 (USD MILLION)
  • TABLE 196. THAILAND INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2024-2030 (USD MILLION)
  • TABLE 197. THAILAND INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 198. THAILAND INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 199. THAILAND INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2018-2023 (USD MILLION)
  • TABLE 200. THAILAND INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2024-2030 (USD MILLION)
  • TABLE 201. THAILAND INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 202. THAILAND INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 203. VIETNAM INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2023 (USD MILLION)
  • TABLE 204. VIETNAM INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2024-2030 (USD MILLION)
  • TABLE 205. VIETNAM INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 206. VIETNAM INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 207. VIETNAM INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2018-2023 (USD MILLION)
  • TABLE 208. VIETNAM INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2024-2030 (USD MILLION)
  • TABLE 209. VIETNAM INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 210. VIETNAM INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 211. EUROPE, MIDDLE EAST & AFRICA INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2023 (USD MILLION)
  • TABLE 212. EUROPE, MIDDLE EAST & AFRICA INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2024-2030 (USD MILLION)
  • TABLE 213. EUROPE, MIDDLE EAST & AFRICA INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 214. EUROPE, MIDDLE EAST & AFRICA INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 215. EUROPE, MIDDLE EAST & AFRICA INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2018-2023 (USD MILLION)
  • TABLE 216. EUROPE, MIDDLE EAST & AFRICA INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2024-2030 (USD MILLION)
  • TABLE 217. EUROPE, MIDDLE EAST & AFRICA INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 218. EUROPE, MIDDLE EAST & AFRICA INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 219. EUROPE, MIDDLE EAST & AFRICA INJECTABLE DRUGS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 220. EUROPE, MIDDLE EAST & AFRICA INJECTABLE DRUGS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 221. DENMARK INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2023 (USD MILLION)
  • TABLE 222. DENMARK INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2024-2030 (USD MILLION)
  • TABLE 223. DENMARK INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 224. DENMARK INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 225. DENMARK INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2018-2023 (USD MILLION)
  • TABLE 226. DENMARK INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2024-2030 (USD MILLION)
  • TABLE 227. DENMARK INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 228. DENMARK INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 229. EGYPT INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2023 (USD MILLION)
  • TABLE 230. EGYPT INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2024-2030 (USD MILLION)
  • TABLE 231. EGYPT INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 232. EGYPT INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 233. EGYPT INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2018-2023 (USD MILLION)
  • TABLE 234. EGYPT INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2024-2030 (USD MILLION)
  • TABLE 235. EGYPT INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 236. EGYPT INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 237. FINLAND INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2023 (USD MILLION)
  • TABLE 238. FINLAND INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2024-2030 (USD MILLION)
  • TABLE 239. FINLAND INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 240. FINLAND INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 241. FINLAND INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2018-2023 (USD MILLION)
  • TABLE 242. FINLAND INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2024-2030 (USD MILLION)
  • TABLE 243. FINLAND INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 244. FINLAND INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 245. FRANCE INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2023 (USD MILLION)
  • TABLE 246. FRANCE INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2024-2030 (USD MILLION)
  • TABLE 247. FRANCE INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 248. FRANCE INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 249. FRANCE INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2018-2023 (USD MILLION)
  • TABLE 250. FRANCE INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2024-2030 (USD MILLION)
  • TABLE 251. FRANCE INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 252. FRANCE INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 253. GERMANY INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2023 (USD MILLION)
  • TABLE 254. GERMANY INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2024-2030 (USD MILLION)
  • TABLE 255. GERMANY INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 256. GERMANY INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 257. GERMANY INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2018-2023 (USD MILLION)
  • TABLE 258. GERMANY INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2024-2030 (USD MILLION)
  • TABLE 259. GERMANY INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 260. GERMANY INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 261. ISRAEL INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2023 (USD MILLION)
  • TABLE 262. ISRAEL INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2024-2030 (USD MILLION)
  • TABLE 263. ISRAEL INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 264. ISRAEL INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 265. ISRAEL INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2018-2023 (USD MILLION)
  • TABLE 266. ISRAEL INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2024-2030 (USD MILLION)
  • TABLE 267. ISRAEL INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 268. ISRAEL INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 269. ITALY INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2023 (USD MILLION)
  • TABLE 270. ITALY INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2024-2030 (USD MILLION)
  • TABLE 271. ITALY INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 272. ITALY INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 273. ITALY INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2018-2023 (USD MILLION)
  • TABLE 274. ITALY INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2024-2030 (USD MILLION)
  • TABLE 275. ITALY INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 276. ITALY INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 277. NETHERLANDS INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2023 (USD MILLION)
  • TABLE 278. NETHERLANDS INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2024-2030 (USD MILLION)
  • TABLE 279. NETHERLANDS INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 280. NETHERLANDS INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 281. NETHERLANDS INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2018-2023 (USD MILLION)
  • TABLE 282. NETHERLANDS INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2024-2030 (USD MILLION)
  • TABLE 283. NETHERLANDS INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 284. NETHERLANDS INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 285. NIGERIA INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2023 (USD MILLION)
  • TABLE 286. NIGERIA INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2024-2030 (USD MILLION)
  • TABLE 287. NIGERIA INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 288. NIGERIA INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 289. NIGERIA INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2018-2023 (USD MILLION)
  • TABLE 290. NIGERIA INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2024-2030 (USD MILLION)
  • TABLE 291. NIGERIA INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 292. NIGERIA INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 293. NORWAY INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2023 (USD MILLION)
  • TABLE 294. NORWAY INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2024-2030 (USD MILLION)
  • TABLE 295. NORWAY INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 296. NORWAY INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 297. NORWAY INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2018-2023 (USD MILLION)
  • TABLE 298. NORWAY INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2024-2030 (USD MILLION)
  • TABLE 299. NORWAY INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 300. NORWAY INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 301. POLAND INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2023 (USD MILLION)
  • TABLE 302. POLAND INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2024-2030 (USD MILLION)
  • TABLE 303. POLAND INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 304. POLAND INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 305. POLAND INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2018-2023 (USD MILLION)
  • TABLE 306. POLAND INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2024-2030 (USD MILLION)
  • TABLE 307. POLAND INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 308. POLAND INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 309. QATAR INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2023 (USD MILLION)
  • TABLE 310. QATAR INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2024-2030 (USD MILLION)
  • TABLE 311. QATAR INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 312. QATAR INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 313. QATAR INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2018-2023 (USD MILLION)
  • TABLE 314. QATAR INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2024-2030 (USD MILLION)
  • TABLE 315. QATAR INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 316. QATAR INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 317. RUSSIA INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2023 (USD MILLION)
  • TABLE 318. RUSSIA INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2024-2030 (USD MILLION)
  • TABLE 319. RUSSIA INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 320. RUSSIA INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 321. RUSSIA INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2018-2023 (USD MILLION)
  • TABLE 322. RUSSIA INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2024-2030 (USD MILLION)
  • TABLE 323. RUSSIA INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 324. RUSSIA INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 325. SAUDI ARABIA INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2023 (USD MILLION)
  • TABLE 326. SAUDI ARABIA INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2024-2030 (USD MILLION)
  • TABLE 327. SAUDI ARABIA INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 328. SAUDI ARABIA INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 329. SAUDI ARABIA INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2018-2023 (USD MILLION)
  • TABLE 330. SAUDI ARABIA INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2024-2030 (USD MILLION)
  • TABLE 331. SAUDI ARABIA INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 332. SAUDI ARABIA INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 333. SOUTH AFRICA INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2023 (USD MILLION)
  • TABLE 334. SOUTH AFRICA INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2024-2030 (USD MILLION)
  • TABLE 335. SOUTH AFRICA INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 336. SOUTH AFRICA INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 337. SOUTH AFRICA INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2018-2023 (USD MILLION)
  • TABLE 338. SOUTH AFRICA INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2024-2030 (USD MILLION)
  • TABLE 339. SOUTH AFRICA INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 340. SOUTH AFRICA INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 341. SPAIN INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2023 (USD MILLION)
  • TABLE 342. SPAIN INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2024-2030 (USD MILLION)
  • TABLE 343. SPAIN INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 344. SPAIN INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 345. SPAIN INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2018-2023 (USD MILLION)
  • TABLE 346. SPAIN INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2024-2030 (USD MILLION)
  • TABLE 347. SPAIN INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 348. SPAIN INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 349. SWEDEN INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2023 (USD MILLION)
  • TABLE 350. SWEDEN INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2024-2030 (USD MILLION)
  • TABLE 351. SWEDEN INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 352. SWEDEN INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 353. SWEDEN INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2018-2023 (USD MILLION)
  • TABLE 354. SWEDEN INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2024-2030 (USD MILLION)
  • TABLE 355. SWEDEN INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 356. SWEDEN INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 357. SWITZERLAND INJECTABLE D